This is a default text for your page Chloe Tucker/Sandbox 1. Click above on edit this page to modify. Be careful with the < and > signs.

You may include any references to papers as in: the use of JSmol in Proteopedia ^[1] or to the article describing Jmol ^[2] to the rescue.

Introduction

Diabetes

Function

^[3].

Disease

Relevance

Structural highlights

This is a sample scene created with SAT to of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.

Binding/Active Site of GIPR with GIP

Figure 1. GIPR and GIP residue interactions

The of GIP with the GIP receptor (GIPR) is where the N-term of GIP binds with the transmembrane domain of the GIPR. The first interaction formed with GIPR and the N-term of GIP is a hydrogen bond between Tyrosine 1 (Y1) and Glutamine 224 (Q224) to activate the G-protein to start sending signals to the cell. Many other within the binding site are forming hydrogen bonds and hydrophobic interactions between the ligand and the receptor. The N-term binds more strongly than the C-term and there are many different residues contributing to this, including, Tyrosine 1 (Y1) and Tryptophan (W296) are forming aromatic interactions. Serine 8 (S8) and Asparagine 290 (N290) are forming two hydrogen bonds with each other. Aspartate 9 (D9) is forming another hydrogen bond with Arginine 370 (R370)^[3]. Figure 1 shows many of the interactions between GIP and GIPR. All of these interactions are responsible for the binding affinity, the strength of the attraction, between the two proteins. These hydrogen bonds lead to the activation of cell signaling and when this binding is somehow disrupted, that is what causes different diseases like diabetes.

Binding/Active Site of GIPR with Tirzepatide

Figure 2. Residue Interactions with Tirzepatide

The with Tirzepatide is the same as GIP with the N-term binding to the transmembrane domain and activating cellular signaling.The are fairly similar just in a different conformations, which is allowing for more hydrogen bonding. Figure 2 shows the interactions between GIPR and Tirzepatide, along with the slight changes in conformation and hydrogen bonding. In Tirzepatide, the most noticeable conformational change is the Tyrosine 1 (Y1) residue. It is now facing up towards Arginine 190 (R190) where they can now form a new hydrogen bond that was not present in GIP. The more hydrogen bonding there is between molecules, the stronger the binding between the two molecules will be. This can lead to the conclusion that GIPR has a higher binding affinity for Tirzepatide than GIP itself^[3].

Isoleucine vs. Threonine

In GIP there is an Isoleucine present . Isoleucine is a branched residue that is very hydrophobic. This residue is also present in the N-term where the important interactions are occuring. In Tirzepatide, this seventh residue has been changed to a Threonine residue . Threonine is also a branched residue, but it contains a hydroxyl group making it hydrophilic, allowing it to make hydrogen bonds. Threonine 7 (T7) is also making a hydrogen bone with the Arginine 190 (R190) residue. This extra hydrogen bond in Tirzepatide is also responsible for a higher binding affinity for the drug than GIP itself.